Literature DB >> 22955007

Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation.

Oliver D Howes1, Francis Vergunst, Siobhan Gee, Philip McGuire, Shitij Kapur, David Taylor.   

Abstract

BACKGROUND: Clozapine is the only antipsychotic drug licensed for treatment-resistant schizophrenia but its use is often delayed. Since previous studies, national guidelines on the use of clozapine and other antipsychotics have been disseminated to clinicians. AIMS: To determine the theoretical delay to clozapine initiation and to quantify the prior use of antipsychotic polypharmacy and high-dose antipsychotic treatment.
METHOD: Clinico-demographic data were extracted from the treatment records of all patients commencing clozapine in our centre between 2006 and 2010.
RESULTS: Complete records were available for 149 patients. The mean theoretical delay in initiating clozapine was 47.7 months (s.d. = 49.7). Before commencing clozapine, antipsychotic polypharmacy and high-dose treatment was evident in 36.2 and 34.2% of patients respectively. Theoretical delay was related to illness duration (β = 0.7, P<0.001) but did not differ by gender or ethnicity.
CONCLUSIONS: Substantial delays to clozapine initiation remain and antipsychotic polypharmacy and high doses are commonly used prior to clozapine, despite treatment guidelines.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22955007     DOI: 10.1192/bjp.bp.111.105833

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  86 in total

Review 1.  Maximizing response to first-line antipsychotics in schizophrenia: a review focused on finding from meta-analysis.

Authors:  Robert C Smith; Stefan Leucht; John M Davis
Journal:  Psychopharmacology (Berl)       Date:  2018-11-30       Impact factor: 4.530

2.  Correlates of Clozapine Use after a First Episode of Schizophrenia: Results From a Long-term Prospective Study.

Authors:  Alp Üçok; Ugur Çıkrıkçılı; Ceylan Ergül; Öznur Tabak; Ada Salaj; Sercan Karabulut; Christoph U Correll
Journal:  CNS Drugs       Date:  2016-10       Impact factor: 5.749

3.  Pathway to clozapine use: a comparison between a patient cohort from New Zealand and a cohort from the United Kingdom.

Authors:  Amanda J Wheeler; Celia L Feetam; Jeff Harrison
Journal:  Clin Drug Investig       Date:  2014-03       Impact factor: 2.859

Review 4.  Guidelines for the Pharmacotherapy of Schizophrenia in Adults.

Authors:  Gary Remington; Donald Addington; William Honer; Zahinoor Ismail; Thomas Raedler; Michael Teehan
Journal:  Can J Psychiatry       Date:  2017-07-13       Impact factor: 4.356

5.  Prescribing pattern of clozapine and other antipsychotics for patients with first-episode psychosis: a cross-sectional survey of early intervention teams.

Authors:  Tongeji E Tungaraza; Wakil Ahmed; Chinonyelum Chira; Erin Turner; Susan Mayaki; Harpal Singh Nandhra; Tom Edwards; Saeed Farooq
Journal:  Ther Adv Psychopharmacol       Date:  2016-12-01

6.  The Differential Binding of Antipsychotic Drugs to the ABC Transporter P-Glycoprotein Predicts Cannabinoid-Antipsychotic Drug Interactions.

Authors:  Natalia I Brzozowska; Erik J de Tonnerre; Kong M Li; Xiao Suo Wang; Aurelie A Boucher; Paul D Callaghan; Michael Kuligowski; Alex Wong; Jonathon C Arnold
Journal:  Neuropsychopharmacology       Date:  2017-03-08       Impact factor: 7.853

7.  Improving outcomes of first-episode psychosis: an overview.

Authors:  Paolo Fusar-Poli; Patrick D McGorry; John M Kane
Journal:  World Psychiatry       Date:  2017-10       Impact factor: 49.548

8.  Clinical Utility and Safety of Slower-than-Recommended Titration of Clozapine for Treatment-Resistant Schizophrenia: a Retrospective Cohort Study.

Authors:  Masaru Tsukahara; Ryuhei So; Yuji Yada; Masafumi Kodama; Yoshiki Kishi
Journal:  Psychiatr Q       Date:  2020-09-05

9.  Presynaptic Dopamine Capacity in Patients with Treatment-Resistant Schizophrenia Taking Clozapine: An [18F]DOPA PET Study.

Authors:  Euitae Kim; Oliver D Howes; Mattia Veronese; Katherine Beck; Seongho Seo; Jin Woo Park; Jae Sung Lee; Yun-Sang Lee; Jun Soo Kwon
Journal:  Neuropsychopharmacology       Date:  2016-11-18       Impact factor: 7.853

10.  Factors associated with non evidence-based prescribing of antipsychotics.

Authors:  Anne Connolly; David Taylor
Journal:  Ther Adv Psychopharmacol       Date:  2014-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.